S'abonner

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial - 07/11/17

Doi : 10.1016/S1470-2045(17)30608-3 
Yi-Long Wu, ProfMD a, , Ying Cheng, MD b, Xiangdong Zhou, MD c, Ki Hyeong Lee, MD d, Kazuhiko Nakagawa, ProfMD e, Seiji Niho, MD f, Fumito Tsuji, MS g, Rolf Linke, MD h, Rafael Rosell, ProfMD i, Jesus Corral, MD j, Maria Rita Migliorino, MD k, Adam Pluzanski, MD l, Eric I Sbar, DO m, Tao Wang, PhD n, Jane Liang White, ScD n, Sashi Nadanaciva, DPhil n, Rickard Sandin, PhD o, Tony S Mok, ProfMD p
a Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China 
b Jilin Provincial Cancer Hospital, Changchun, China 
c First Affiliated Hospital of Third Military Medical University, Chongqing, China 
d Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea 
e Kindai University Hospital, Osaka, Japan 
f National Cancer Center Hospital East, Kashiwa, Japan 
g SFJ Pharma Japan, Osaka, Japan 
h SFJ Pharmaceuticals Group, Pleasanton, CA, USA 
i Catalan Institute of Oncology, Barcelona, Spain 
j Hospital Universitario Virgen del Rocio, Seville, Spain 
k Pulmonary Oncology Unit, San Camillo-Forlanini Hospital, Rome, Italy 
l The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland 
m Pfizer, Collegeville, PA, USA 
n Pfizer, Groton, CT, USA 
o Pfizer, Sollentuna, Sweden 
p State Key Laboratory of South China, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, China 

* Correspondence to: Prof Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou 510080, China Guangdong Lung Cancer Institute Guangdong General Hospital and Guangdong Academy of Medical Sciences Guangzhou 510080 China

Summary

Background

Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC).

Methods

In this international, multicentre, randomised, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centres and university hospitals in seven countries or special administrative regions. We randomly assigned participants (1:1) to receive oral dacomitinib 45 mg/day (in 28-day cycles) or oral gefitinib 250 mg/day (in 28-day cycles) until disease progression or another discontinuation criterion was met. Randomisation, stratified by race and EGFR mutation type, was done with a computer-generated random code assigned by a central interactive web response system. The primary endpoint was progression-free survival assessed by masked independent review in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, number NCT01774721, and is ongoing but no longer recruiting patients.

Findings

Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive dacomitinib (n=227) or gefitinib (n=225). Median duration of follow-up for progression-free survival was 22·1 months (95% CI 20·3–23·9). Median progression-free survival according to masked independent review was 14·7 months (95% CI 11·1–16·6) in the dacomitinib group and 9·2 months (9·1–11·0) in the gefitinib group (hazard ratio 0·59, 95% CI 0·47–0·74; p<0·0001). The most common grade 3–4 adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs none of 224 patients given gefitinib), diarrhoea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels (two [1%] vs 19 [8%]). Treatment-related serious adverse events were reported in 21 (9%) patients given dacomitinib and in ten (4%) patients given gefitinib. Two treatment-related deaths occurred in the dacomitinib group (one related to untreated diarrhoea and one to untreated cholelithases/liver disease) and one in the gefitinib group (related to sigmoid colon diverticulitis/rupture complicated by pneumonia).

Interpretation

Dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-positive NSCLC and should be considered as a new treatment option for this population.

Funding

SFJ Pharmaceuticals Group and Pfizer.

Le texte complet de cet article est disponible en PDF.

Plan


© 2017  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 18 - N° 11

P. 1454-1466 - novembre 2017 Retour au numéro
Article précédent Article précédent
  • Effect of patient choice and hospital competition on service configuration and technology adoption within cancer surgery: a national, population-based study
  • Ajay Aggarwal, Daniel Lewis, Malcolm Mason, Arnie Purushotham, Richard Sullivan, Jan van der Meulen
| Article suivant Article suivant
  • Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
  • Daniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, André M Murad, Salah-Eddin Al-Batran, David H Ilson, Sergei Tjulandin, Evengy Gotovkin, Boguslawa Karaszewska, Igor Bondarenko, Mohamedtaki A Tejani, Anghel A Udrea, Mustapha Tehfe, Ferdinando De Vita, Cheryl Turkington, Rui Tang, Agnes Ang, Yilong Zhang, Tien Hoang, Roger Sidhu, David Cunningham

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.